Here’s a breakdown of the key information from the provided text, focusing on GSK‘s acquisition of Rapt Therapeutics and the drug ozureprubart:
The Deal:
* GSK is acquiring Rapt Therapeutics for approximately $2.2 billion (net payment estimated at $1.9 billion after accounting for Rapt’s cash).
* The deal requires approval from a majority of rapt shareholders.
Ozureprubart (the key asset):
* What it is: A drug in growth for food allergies. It’s a potential “best-in-class” treatment for IgE-mediated diseases.
* How it effectively works: It aims to provide sustained protection with dosing every 8 or 12 weeks, a significant advancement over current treatments that require injections as frequently as every two weeks.
* Clinical Trials: Currently in a placebo-controlled study with participants aged 12-55 with confirmed food allergies. Data is expected next year.
* Potential: Could address patients with high baseline IgE levels who can’t use Xolair. Analysts believe it has “multi-blockbuster” potential (>$1 billion in sales).
* Origin: Licensed from Shanghai Jeyou Pharmaceutical Co.(Rapt has global rights excluding china, Hong Kong, Macau, and Taiwan).
* Financials: Rapt paid $35 million upfront and could pay up to $672.5 million in milestone payments. GSK will assume these obligations.
GSK’s Strategy & Rationale:
* Strategic Fit: Aligns with GSK’s expertise in respiratory, immunology, and inflammation (RI&I). Leverages existing relationships with allergists.
* Pipeline Growth: builds on GSK’s recent investments in immunology, including acquisitions of efimosfermin (for MASH) and drug candidates from Empirico and Hengrui Pharma.
* Reduced Regulatory Risk: Leerink Partners believes there’s no overlap with GSK’s existing immunology pipeline, lowering regulatory hurdles.
Rapt Therapeutics – Other Assets:
* Tivumecirnon: A cancer drug in development, for which Rapt is seeking a partner.
* Zelnecirnon: A previous programme for asthma and atopic dermatitis that was discontinued after the FDA placed tests on clinical hold due to a report of liver failure.
Worth a look